Federal Compounding Status

Where each peptide and GLP-1 in our database stands under federal compounding rules: the FDA 503A bulk drug substances list (the significant-safety-risk Category 2 list and withdrawn nominations) and FDA-approved-drug status. Each entry below is validated by an automated check that matches the compound name against the live FDA list page, so every Category 2 and withdrawn entry links to the exact FDA page that names it. We do not publish a federal status we cannot validate against a primary FDA source: 23 compounds whose status we could not confirm are intentionally omitted from this list rather than guessed.

Last updated 2026-06-02. This page reports public FDA regulatory status for informational purposes only. It is not legal advice, it does not tell you whether you may obtain any compound, and it does not cover state pharmacy-board rules, which vary by state and change frequently. Federal compounding status shifts fast; confirm current status with a licensed pharmacist and the FDA source linked on each entry.

503A/503B Category 2: significant safety risk (5)

• 2023
  GHRP-2

  The FDA placed this substance (503B) in Category 2 of its interim bulk-substances policy, the list it has identified as presenting potential significant safety risks, so it is not eligible for routine pharmacy compounding. FDA source

• 2023
  GHRP-6

  The FDA placed this substance (503B) in Category 2 of its interim bulk-substances policy, the list it has identified as presenting potential significant safety risks, so it is not eligible for routine pharmacy compounding. FDA source

• 2023
  Ipamorelin

  The FDA placed this substance (503B) in Category 2 of its interim bulk-substances policy, the list it has identified as presenting potential significant safety risks, so it is not eligible for routine pharmacy compounding. FDA source

• 2023
  Kisspeptin

  The FDA placed this substance (503A) in Category 2 of its interim bulk-substances policy, the list it has identified as presenting potential significant safety risks, so it is not eligible for routine pharmacy compounding. FDA source

• 2023
  MK-677

  The FDA placed this substance (503A) in Category 2 of its interim bulk-substances policy, the list it has identified as presenting potential significant safety risks, so it is not eligible for routine pharmacy compounding. FDA source

Nomination withdrawn (was Category 2) (15)

• 2026-06-02
  AOD-9604

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  BPC-157

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  CJC-1295

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  DSIP

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Epitalon

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  GHK-Cu

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  KPV

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  LL-37

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Melanotan II

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  MOTS-c

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  PEG-MGF

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Selank

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Semax

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Thymosin Alpha-1

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

• 2026-06-02
  Thymosin Beta-4

  This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

FDA-approved drug (16)

• 2026-06-02
  Afamelanotide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Albiglutide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Bremelanotide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Dulaglutide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Elamipretide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Exenatide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Gonadorelin

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  hCG

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Liraglutide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Lixisenatide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Orforglipron

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Oxytocin

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Semaglutide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Setmelanotide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Tesamorelin

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

• 2026-06-02
  Tirzepatide

  An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.